Skip to content

Cytek Biosciences, Inc. CTKB Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin51.8%-3.6pp55.4%-1.3pp56.7%-4.9pp61.6%-0.3pp
Operating margin-20%-14.4%-13.3pp-1.2%-8.3pp
Net margin-33%1.5%
Returns
Return on equity-18%0.6%
Return on invested capital-12.6%-14.4%-12.6pp-1.9%
Efficiency
Asset turnover0.4×0.0×0.4×0.0×0.4×0.0×0.3×0.0×
Liquidity
Current ratio-0.8×5.9×-1.1×-2.3×9.3×-3.8×
Leverage
Debt-to-equity0.1×0.0×0.0×0.0×0.0×
Per Share
Book value per share$2.68-11.7%$3.03+4.3%$2.91-5.4%$3.07-38.2%
Valuation
Market capitalization$577.27M+54.5%$835.98M-29.9%$1.19B-13.7%$1.38B-36.8%
Price / sales2.8×+0.9×4.2×-2.0×6.2×-2.2×8.4×-8.7×
Price / book1.8×+0.8×2.1×-0.9×-0.2×3.2×-2.1×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Cytek Biosciences, Inc.'s profit margins?
Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
Where do Cytek Biosciences, Inc.'s ratios come from?
Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.